These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 27436880)

  • 1. Higher Visit-to-Visit Low-Density Lipoprotein Cholesterol Variability Is Associated With Lower Cognitive Performance, Lower Cerebral Blood Flow, and Greater White Matter Hyperintensity Load in Older Subjects.
    Smit RA; Trompet S; Sabayan B; le Cessie S; van der Grond J; van Buchem MA; de Craen AJ; Jukema JW
    Circulation; 2016 Jul; 134(3):212-21. PubMed ID: 27436880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of visit-to-visit variability in blood pressure with cognitive function in old age: prospective cohort study.
    Sabayan B; Wijsman LW; Foster-Dingley JC; Stott DJ; Ford I; Buckley BM; Sattar N; Jukema JW; van Osch MJ; van der Grond J; van Buchem MA; Westendorp RG; de Craen AJ; Mooijaart SP
    BMJ; 2013 Jul; 347():f4600. PubMed ID: 23900315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline levels of low-density lipoprotein cholesterol and lipoprotein (a) and the AvaII polymorphism of the low-density lipoprotein receptor gene influence the response of low-density lipoprotein cholesterol to pravastatin treatment.
    Lahoz C; Peña R; Mostaza JM; Laguna F; García-Iglesias MF; Taboada M; Pintó X
    Metabolism; 2005 Jun; 54(6):741-7. PubMed ID: 15931608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of withdrawal of pravastatin therapy on C-reactive protein and low-density lipoprotein cholesterol.
    van der Harst P; Asselbergs FW; Hillege HL; Bakker SJ; Voors AA; van Veldhuisen DJ; van Gilst WH;
    Am J Cardiol; 2007 Nov; 100(10):1548-51. PubMed ID: 17996517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of High-Density Lipoprotein Cholesterol With Cognitive Function: Findings From the PROspective Study of Pravastatin in the Elderly at Risk.
    Grasset L; Smit RAJ; Caunca MR; Elfassy T; Odden MC; van der Grond J; van Buchem MA; Stott DJ; Sattar N; Trompet S; Jukema JW; Zeki Al Hazzouri A
    J Aging Health; 2020 Oct; 32(9):1267-1274. PubMed ID: 32456512
    [No Abstract]   [Full Text] [Related]  

  • 6. Visit-to-visit low-density lipoprotein cholesterol variability and risk of cardiovascular outcomes: insights from the TNT trial.
    Bangalore S; Breazna A; DeMicco DA; Wun CC; Messerli FH;
    J Am Coll Cardiol; 2015 Apr; 65(15):1539-48. PubMed ID: 25881936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
    Tani S; Nagao K; Hirayama A
    Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
    Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glasziou P; White H; Barter P; Tonkin A;
    Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-reactive protein levels and outcomes after statin therapy.
    Ridker PM; Cannon CP; Morrow D; Rifai N; Rose LM; McCabe CH; Pfeffer MA; Braunwald E;
    N Engl J Med; 2005 Jan; 352(1):20-8. PubMed ID: 15635109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between apolipoprotein E4 and cognitive decline in elderly adults.
    Packard CJ; Westendorp RG; Stott DJ; Caslake MJ; Murray HM; Shepherd J; Blauw GJ; Murphy MB; Bollen EL; Buckley BM; Cobbe SM; Ford I; Gaw A; Hyland M; Jukema JW; Kamper AM; Macfarlane PW; Jolles J; Perry IJ; Sweeney BJ; Twomey C;
    J Am Geriatr Soc; 2007 Nov; 55(11):1777-85. PubMed ID: 17979899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER).
    Packard CJ; Ford I; Robertson M; Shepherd J; Blauw GJ; Murphy MB; Bollen EL; Buckley BM; Cobbe SM; Gaw A; Hyland M; Jukema JW; Kamper AM; Macfarlane PW; Perry IJ; Stott DJ; Sweeney BJ; Twomey C; Westendorp RG;
    Circulation; 2005 Nov; 112(20):3058-65. PubMed ID: 16275871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of effect of pravastatin on cerebral blood flow or parenchymal volume loss in elderly at risk for vascular disease.
    ten Dam VH; Box FM; de Craen AJ; van den Heuvel DM; Bollen EL; Murray HM; van Buchem MA; Westendorp RG; Blauw GJ;
    Stroke; 2005 Aug; 36(8):1633-6. PubMed ID: 16049200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
    Harley CR; Gandhi SK; Heien H; McDonough K; Nelson SP
    Expert Opin Pharmacother; 2008 Apr; 9(5):669-76. PubMed ID: 18345946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive Function in Dementia-Free Subjects and Survival in Old Age: The PROSPER Study.
    Rostamian S; de Haan S; van der Grond J; van Buchem MA; Ford I; Jukema JW; Sabayan B
    Am J Med; 2019 Dec; 132(12):1466-1474.e4. PubMed ID: 31228412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial.
    Mora S; Caulfield MP; Wohlgemuth J; Chen Z; Superko HR; Rowland CM; Glynn RJ; Ridker PM; Krauss RM
    Circulation; 2015 Dec; 132(23):2220-9. PubMed ID: 26408274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-density lipoprotein receptor genotype and response to pravastatin in children with familial hypercholesterolemia: substudy of an intima-media thickness trial.
    Koeijvoets KC; Rodenburg J; Hutten BA; Wiegman A; Kastelein JJ; Sijbrands EJ
    Circulation; 2005 Nov; 112(20):3168-73. PubMed ID: 16286607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations between low circulatory low-density lipoprotein cholesterol level and brain health in non-stroke non-demented subjects.
    Chung CP; Chou KH; Peng LN; Liu LK; Lee WJ; Chen LK; Lin CP; Wang PN
    Neuroimage; 2018 Nov; 181():627-634. PubMed ID: 30053515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.